Filing Flows › Pfizer (PFE) › Guidance history
Pfizer (PFE) guidance history: what it guided and what it reported
Pfizer gave guidance in 14 earnings releases on file since Jan 30, 2024. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +1.0% against the guided midpoint. Its releases raised guidance 8 times and lowered it 3 times.
Revenue
Met or beat 2 of 2 periods (0 above, 2 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $59.5B–$62.5B (Feb 3, 2026) → raised $62.0B–$64.0B (Nov 3, 2026) | — | to be reported | — |
| FY2025 | $61.0B–$64.0B (Feb 4, 2025) → reaffirmed $61.0B–$64.0B (Apr 29, 2025) → reaffirmed $61.0B–$64.0B (Aug 5, 2025) → reaffirmed $61.0B–$64.0B (Nov 4, 2025) | $62.6B | within the range | +0.1% |
| FY2024 | $58.5B–$61.5B (Jan 30, 2024) → reaffirmed $58.5B–$61.5B (May 1, 2024) → raised $59.5B–$62.5B (Jul 30, 2024) → raised $61.0B–$64.0B (Oct 29, 2024) | $63.6B | within the range | +1.8% |
Adjusted revenue
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2024 | $58.5B–$61.5B (Jan 30, 2024) | — | — | — |
GAAP EPS
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2024 | −$4.00 (Jul 30, 2024) | — | — | — |
Interest expense
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2024 | $31.0B (Oct 29, 2024) | — | — | — |
Adjusted EPS
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $2.80–$3.00 (Feb 3, 2026) → reaffirmed $2.80–$3.00 (May 5, 2026) → reaffirmed $2.80–$3.00 (Aug 4, 2026) → lowered −$2.00 (Nov 3, 2026) | — | to be reported | — |
| FY2025 | $2.80–$3.00 (Feb 4, 2025) → reaffirmed $2.80–$3.00 (Apr 29, 2025) → raised $2.90–$3.10 (Aug 5, 2025) → lowered −$1.00 (Nov 4, 2025) | — | — | — |
| FY2024 | $2.05–$2.25 (Jan 30, 2024) → raised $2.15–$2.35 (May 1, 2024) → raised $2.45–$2.65 (Jul 30, 2024) → raised $2.75–$2.95 (Oct 29, 2024) | — | — | — |
The latest quarter
Pfizer, Q3 2026: revenue $16.6B (-0.4% year over year), operating margin 20.4%, net earnings $3.3B, operating cash flow $5.4B. The chart follows the revenue to costs, profit and cash.
Questions
Does Pfizer beat its guidance?
Pfizer gave guidance in 14 earnings releases on file since Jan 30, 2024. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +1.0% against the guided midpoint.
How often does Pfizer raise guidance?
Its earnings releases raised guidance 8 times and lowered it 3 times since Jan 30, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.